These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3068260)

  • 1. Epoprostenol (PGI2, prostacyclin) during high-risk hemodialysis: preventing further bleeding complications.
    Swartz RD; Flamenbaum W; Dubrow A; Hall JC; Crow JW; Cato A
    J Clin Pharmacol; 1988 Sep; 28(9):818-25. PubMed ID: 3068260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent.
    Zusman RM; Rubin RH; Cato AE; Cocchetto DM; Crow JW; Tolkoff-Rubin N
    N Engl J Med; 1981 Apr; 304(16):934-9. PubMed ID: 7010166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis.
    Caruana RJ; Smith MC; Clyne D; Crow JW; Zinn JM; Diehl JH
    Blood Purif; 1991; 9(5-6):296-304. PubMed ID: 1819317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostacyclin substitution for heparin in long-term hemodialysis.
    Smith MC; Danviriyasup K; Crow JW; Cato AE; Park GD; Hassid A; Dunn MJ
    Am J Med; 1982 Nov; 73(5):669-78. PubMed ID: 6753575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of epoprostenol (PGI2) versus heparin (H) in hemodialysis (HD).
    Dubrow A; Flamenbaum W; Mittman N; Hall J; Zinn J
    Trans Am Soc Artif Intern Organs; 1984; 30():52-4. PubMed ID: 6398552
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostacyclin (epoprostenol) as the sole antithrombotic agent in postdilutional hemofiltration.
    Canaud B; Mion C; Arujo A; N'Guyen QV; Paleyrac G; Hemmendinger S; Cazenave JP
    Nephron; 1988; 48(3):206-12. PubMed ID: 2965311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of coagulation during hemodialysis by a combination of the stable prostacyclin analogue CG 4203 and low-dose heparin.
    Maurin N; Ballmann M
    Clin Nephrol; 1988 Jul; 30(1):35-41. PubMed ID: 3061692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemodialysis with prostacyclin (Epoprostenol) alone.
    Rylance PB; Gordge MP; Ireland H; Lane DA; Weston MJ
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():281-6. PubMed ID: 3887374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostacyclin versus citrate in continuous haemodiafiltration: an observational study in patients with high risk of bleeding.
    Balik M; Waldauf P; Plásil P; Pachl J
    Blood Purif; 2005; 23(4):325-9. PubMed ID: 16118487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the effectiveness of hemodialysis using only heparin or prostacyclin with heparin].
    Kuźniewski M; Sułowicz W
    Przegl Lek; 1990; 47(3):328-31. PubMed ID: 2236625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostacyclin and thromboxane in chronic uremia: effect of hemodialysis.
    Ylikorkala O; Huttunen K; Järvi J; Viinikka L
    Clin Nephrol; 1982 Aug; 18(2):83-7. PubMed ID: 6754193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing hemorrhage in high-risk hemodialysis: regional versus low-dose heparin.
    Swartz RD; Port FK
    Kidney Int; 1979 Oct; 16(4):513-8. PubMed ID: 548596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vitro bleeding time while using a stable prostacyclin analogue during hemodialysis.
    Maurin N
    Int J Artif Organs; 1988 Jul; 11(4):243-8. PubMed ID: 3045018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostacyclin safer than heparin in haemodialysis.
    Arze RS; Ward MK
    Lancet; 1981 Jul; 2(8236):50. PubMed ID: 6113427
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostacyclin and heparin during haemodialysis: comparative effects.
    Camici M; Evangelisti L
    Life Support Syst; 1986; 4(3):205-9. PubMed ID: 3537544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding.
    Evenepoel P; Dejagere T; Verhamme P; Claes K; Kuypers D; Bammens B; Vanrenterghem Y
    Am J Kidney Dis; 2007 May; 49(5):642-9. PubMed ID: 17472846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimizing hemorrhagic complications in dialysis patients.
    Lohr JW; Schwab SJ
    J Am Soc Nephrol; 1991 Nov; 2(5):961-75. PubMed ID: 1760540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodialysis without Systemic Anticoagulation: A Randomized Controlled Trial to Evaluate Five Strategies in Patients at a High Risk of Bleeding.
    Gois PHF; McIntyre D; Ratanjee S; Pelecanos A; Scuderi C; Janoschka CL; Summers K; Wu H; Elford B; Ranganathan D; Healy HG
    Med Sci (Basel); 2024 Aug; 12(3):. PubMed ID: 39189201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure.
    Davenport A; Will EJ; Davison AM
    Nephron; 1994; 66(4):431-7. PubMed ID: 8015647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.